OLMA - CIK 0001750284
The table below shows Olema Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $49.23M | $39.95M | $43.90M | $30.62M | $33.23M | $29.11M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.75M |
| $5.93M |
| $3.96M |
| $4.25M |
| $4.39M |
| $4.42M |
| Operating income | -$57.99M | -$45.88M | -$47.86M | -$34.87M | -$37.62M | -$33.53M |
| Income tax | - | - | - | - | - | - |
| Net income | -$53.09M | -$42.22M | -$43.78M | -$30.39M | -$34.55M | -$30.38M |
| EPS (diluted) | -$0.52 | -$0.49 | -$0.51 | -$0.36 | -$0.60 | -$0.54 |